Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: Systematic review and meta-analysis of prospective controlled studies

Journal of Viral Hepatitis

Volumn 15, Issue 10, 2008, Pages 699-709

  Xirouchakis, E ^a   Triantos, C ^a   Manousou, P ^a   Sigalas, A ^a   Calvaruso, V ^a   Corbani, A ^a   Leandro, G ^b   Patch, D ^a   Burroughs, A ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

Cirrhosis; HCV; Pegylated interferon; Ribavirin; Transplantation

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; STEROID; TACROLIMUS;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; GRAFT REJECTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER GRAFT; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SYSTEMATIC REVIEW;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBAVIRIN; TREATMENT OUTCOME;

EID: 52149121573     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2008.01019.x     Document Type: Review

References (65)

1. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002 122 (4 889 896.
2. Samuel D, Forns X, Berenguer M et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol 2006 45 (1 127 143.
3. Triantos C, Samonakis D, Stigliano R, Thalheimer U, Patch D, Burroughs A. Liver transplantation and hepatitis C virus: systematic review of antiviral therapy. Transplantation 2005 79 (3 261 268.
4. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 (9286 958 965.
5. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 (13 975 982.
6. Hadziyannis SJ, Sette H Jr., Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 (5 346 355.
7. Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl 2006 12 (8 1192 1204.
8. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006 6 (7 1586 1599.
9. Arjal RR, Burton JR Jr, Villamil F, Rosen HR. Review article: the treatment of hepatitis C virus recurrence after liver transplantation. Aliment Pharmacol Ther 2007 26 (2 127 140.
10. Samuel D, Bizollon T, Feray T et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003 124 (3 642 650.
11. Ahmad J, Dodson SF, Demetris AJ, Fung JJ, Shakil AO. Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin. Liver Transpl 2001 7 (10 863 869.
12. Castells L, Vargas V, Allende H et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005 43 (1 53 59.
13. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996 17 (1 1 12.
14. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988 318 : 1728 1733.
15. Leandro G. Meta-Analysis in Medical Research. Oxford : Blackwell Publishing Ltd, 2004.
16. Moreno Planas JM, Rubio GE, Boullosa GE et al. Effectiveness of pegylated interferon and ribavirin in patients with liver HCV cirrhosis. Transplant Proc 2005 37 (3 1482 1483.
17. Helbling B, Jochum W, Stamenic I et al. HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. J Viral Hepat 2006 13 (11 762 769.
18. Iacobellis A, Siciliano M, Perri F et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007 46 (2 206 212.
19. Di MV, Almasio PL, Ferraro D et al. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 2007 47 (4 484 491.
20. Massoumi H, Elsiesy H, Peterson B et al. Treatment of cirrhotic patients with HCV referred for liver transplantation using an escalating dose regimen of pegylated interferon alpha-2A and ribavirin (Abstract). Hepatology 2006 44 (Suppl 1 312A.
21. Annicchiarico BE, Siciliano M, Parente P, Gasbarrini A, Bombardieri G. Hepatic function is a strong predictive factor of efficacy and safety of antiviral therapy in portal hypertensive hepatitis C virous-related liver cirrhosis (Abstract). J Hepatol 2007 46 (Suppl 1 S216.
22. Thorat VK. Maitenance pegylated IFN given once every three weeks prevents relapse of hepatitis C virus (HCV) in decompensated cirrhosis (Abstract). Hepatology 2006 44 (Suppl 1 332A.
23. Bruno S, Maisonneuve P, Pockros PJ et al. Efficacy and safety of peginterferon alpha-2a(40Kd) plus ribavirin in HCV patients with complete cirrhosis (knodell score F4) (Abstract). Hepatology 2006 44 (Suppl 1 332A 333A.
24. Marcellin P, Roberts S, Alberti A et al. Impact of baseline hepatitis C virus (HCV) RNA and genotype on the efficacy of peginterferon alpha-2a (40Kd) plus ribavirin in patients with compensated cirrhosis/bridging fibrosis (Abstract). Hepatology 2005 42 (Suppl 1 672A.
25. Lim JK, Imperial JC. Safety and efficacy of antiviral therapy in patients with decompensated cirrhosis associated with chronic Hepatitis C infection (Abstract). Gastroenterology 2006 130 (Suppl 2 A719.
26. Shergill AK, Khalili M, Straley S et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005 5 (1 118 124.
27. Merhav HJ, Mieles L, Ottman M, Pappas SC, Botero RC. Preemptive treatment of HCV after liver transplantation is unjustified except for genotype 3A (Abstract). Hepatology 2007 46 (Suppl 1 344A.
28. Castedal M, Felldin M, Backman L, Olausson M, Friman S. Preemptive therapy with pegylated interferon alpha-2b and ribavirin after liver transplantation for hepatitis C cirrhosis. Transplant Proc 2005 37 (8 3313 3314.
29. Kuo A, Lan B, Feng S, Terrault NA. Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus (HCV) infection (Abstract). Hepatology 2006 44 (Suppl 1 189A.
30. Fernandez I, Meneu JC, Colina F et al. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 2006 12 (12 1805 1812.
31. Oton E, Barcena R, Moreno-Planas JM et al. Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant 2006 6 (10 2348 2355.
32. Babatin M, Schindel L, Burak KW. Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy. Can J Gastroenterol 2005 19 (6 359 365.
33. Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004 40 (4 669 674.
34. Ross AS, Bhan AK, Pascual M, Thiim M, Benedict CA, Chung RT. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transplant 2004 18 (2 166 173.
35. Rodriguez-Luna H, Khatib A, Sharma P et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation 2004 77 (2 190 194.
36. Stravitz RT, Shiffman ML, Sanyal AJ et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 2004 10 (7 850 858.
37. Bizollon T, Pradat P, Mabrut JY et al. Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection posttransplantation. Am J Transplant 2007 7 (2 448 453.
38. Neumann U, Puhl G, Bahra M et al. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. Transplantation 2006 82 (1 43 47.
39. Mukherjee S, Lyden E. Impact of pegylated interferon alpha-2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series. Liver Int 2006 26 (5 529 535.
40. Toniutto P, Fabris C, Fumo E et al. Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: comparison of tolerability and efficacy. J Gastroenterol Hepatol 2005 20 (4 577 582.
41. Neff GW, Montalbano M, O'Brien CB et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004 78 (9 1303 1307.
42. Mukherjee S, Lyden E. Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series. Hepatogastroenterology 2006 53 (70 561 565.
43. Angelico M, Petrolati A, Lionetti R et al. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007 46 (6 1009 1017.
44. Picciotto FP, Tritto G, Lanza AG et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007 46 (3 459 465.
45. Moreno-Planas JM, Rubio-Gonzalez E, Bullosa Grana E et al. Peginterferon and ribavirin in patients with HCV cirrhosis after liver transplantation. Transplant Proc 2005 37 (5 2207 2208.
46. Carrion JA, Navasa M, Garcia-Retortillo M et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007 132 (5 1746 1756.
47. Cicinnati VR, Iacob S, Klein CG et al. Ribavirin with either standard or pegylated interferon to treat recurrent hepatitis C after liver transplantation. Aliment Pharmacol Ther 2007 26 (2 291 303.
48. Sharma P, Marrero JA, Fontana RJ et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl 2007 13 (8 1100 1108.
49. Gordon F, Denis M, Davis C et al. High sustained virological response (SVR) in HCV treatment with peginterferon-alfa 2b and ribavirin after liver transplantation (Abstract). Am J Transplant 2005 5 (s11 181.
50. Verna E, Gaglio PJ, Dove LM, Kinkhabwala M, Emond JC, Brown RS. Efficacy and safety of prolonged interferon and ribavirin for recurrent hepatitis C following orthotopic liver transplantation (Abstract). Am J Transplant 2006 6 (s2 540.
51. Chadalavada R, Sass D, Shaikh O et al. Comparison of pegylated interferon alpha 2a and ribavirin vs pegylated interferon alpha 2b and ribavirin for treatment of recurrent hepatitis C after liver transplantation (Abstract). Am J Transplant 2006 6 (s2 540 541.
52. Ghalib R, Levine C, Hollinger B et al. Sustained viral response using PEG INF alfa-2b plus ribavirin in patients with recurrent hepatitis C after liver transplantation (Abstract). Hepatology 2006 44 (Suppl 1 478A.
53. Chacko K, Sussman N, Vierling JM et al. Adherence to the 80/80/80 rule in treatment of HCV recurrence after OLT is strongly associated with sustained virologic response (Abstract). Hepatology 2006 44 (Suppl 1 482A.
54. Samanta A, Mandalapu A, Fisher A et al. Treatment with combination Peginterferon alfa-2b and ribavirin of recurrent hepatitis C in liver transplant recipients non responsive to interferon alfa-2b and ribavirin (Abstract). Gastroenterology 2006 130 (Suppl 2 A495.
55. Selzner N, Guindi M, Girgrah N, Wong P, Levy G, Lilly L. Sustained virological response to antiviral therapy for recurrent HCV post liver transplant favorably influences histological progression (Abstract). Hepatology 2006 44 (Suppl 1 479A 480A.
56. Casanovas-Taltavull T, Llobet M, Casanova A et al. Predictive factors of early and sustained viral response in patients with recurrent hepatitis C after liver transplantation treated with combined therapy (Abstract). Hepatology 2005 42 (Suppl 1 487A.
57. Benlloch S, Berenguer M, Fernandez A et al. Antiviral therapy for HCV-1b liver transplant recipients: better results with younger grafts (Abstract). Hepatology 2005 42 (Suppl 1 489A.
58. Lilly L, Girgrah N, Al Alwan A et al. On treatment virological response of 70% in 100 patients treated with combination antiviral therapy for recurrent HCV following liver transplantation (Abstract). Hepatology 2005 42 (Suppl 1 489A.
59. Samuel D. Treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon and ribavirin (Abstract). Hepatology 2003 34 (Suppl 1 531A.
60. Lorenzini S, Biselli A, Gramenzi F et al. Pegylated interferon plus ribavirin for the treatment of recurrent HCV infection after liver transplantation (Abstract). J Hepatol 2004 40 (Suppl 1 144.
61. Bergk A, Neumann UP, Van Boemmel F, Wiedenmann B, Berg T, Neuhaus R. Prediction of treatment response to 72 weeks of pegylated interferon alfa-2a plus ribavirin for chronic hepatitis C after liver transplantation (Abstract). J Hepatol 2007 46 (Suppl 1 S218.
62. Martini S, Lavezzo B, Saettone S et al. Pegylated interferon a-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C (Abstract). J Hepatol 2005 42 (Suppl 2 55.
63. Calmus Y, Duvoux C, Pageaux GP et al. Multicenter Randomized Trial in HCV-infected patients treated with Peginterferon alfa-2a and Ribavirin followed by Ribavirin alone after liver transplantation: final report (Abstract). Hepatology 2007 46 (Suppl 1 473A.
64. Cholongitas E, Samonakis D, Patch D et al. Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent hepatitis C virus. Transplantation 2006 81 (3 488 490.
65. Berardi S, Lodato F, Gramenzi A et al. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut 2007 56 (2 237 242.